Edwards Lifesciences

Revenue is anchored by recurring procedure volumes tied to aging demographics and widening indications, with diversified geography (58 percent U.S., 42 percent OUS) and three product groups (TAVR, TMTT, Surgical).

TAVR has shown resilient mid‑single to high‑single digit growth guidance into 2026. Pipeline events (moderate AS, tricuspid therapies) add upside but introduce trial and regulatory risk that can create step‑function changes rather than linear growth.

Overall visibility is high relative to most medtech, yet not as toll‑like as payment networks due to procedure dynamics and policy shifts.